ArticleScientific reports2025
A novel neuroimaging based early detection framework for alzheimer disease using deep learning.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Advances in artificial intelligence for neuroimaging.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2026Review
- A deep residual attention-Recurrent model for early and multi-stage Alzheimer's disease detection.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that significantly impacts cognitive function, posing a major global health challenge. Despite its rising prevalence, particularly in low and middle-income countries, early diagnosis remains inadequate, with projections estimating over 55 million affected individuals by 2022, expected to triple by 2050. Accurate early detection is critical for effective intervention. This study presents Neuroimaging-based Early Detection of Alzheimer's Disease using Deep Learning (NEDA-DL), a novel computer-aided diagnostic (CAD) framework leveraging a hybrid ResNet-50 and AlexNet architecture optimized with CUDA-based parallel processing. The proposed deep learning model processes MRI and PET neuroimaging data, utilizing depthwise separable convolutions to enhance computational efficiency. Performance evaluation using key metrics including accuracy, sensitivity, specificity, and F1-score demonstrates state-of-the-art classification performance, with the Softmax classifier achieving 99.87% accuracy. Comparative analyses further validate the superiority of NEDA-DL over existing methods. By integrating structural and functional neuroimaging insights, this approach enhances diagnostic precision and supports clinical decision-making in Alzheimer's disease detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.